Vijaypd Ceutical Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Vijaypd Ceutical Limited's achieved publicly listed status following its IPO debut on Oct 07, 2025 at the NSE platform. The offering successfully mobilized 55,00,000 Shares, with 55,00,000 Shares allocated to corporate growth initiatives.
Investment participation occurred within the established price band of ₹35 to ₹35, starting from minimum lots of 4000 shares. The subscription window from Sep 29, 2025 through Oct 01, 2025 enabled investor participation across market segments.
Share allocation was completed on Oct 03, 2025, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in October 1971, Vijaypd Ceutical Limited is a pharmaceutical distributor that supplies a wide range of pharmaceutical products and consumer goods while offering comprehensive services. The company operates in various capacities, including as representatives, dealers, agents, stockists, suppliers, traders, and packers. It caters to the pharmaceutical, wellness, and FMCG sectors, offering a diverse portfolio that includes medicines such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral products. Additionally, the company supplies vitamins, hormones, enzymes, wellness tonics, serums, diagnostic test kits, personal care items like soaps, sanitizers, and baby care products, as well as ayurvedic products, cosmetics, food items, dental products, and crude drugs. As of March 31, 2025, Vijaypd Ceutical Limited serves over 2,109 pharmacies, clinics, and nursing homes across four districts, spanning 20 locations. Its extensive distribution network connects with more than 170 healthcare product manufacturers, offering access to over 19,000 stock-keeping units (SKUs). This wide-ranging portfolio enables the company to effectively meet customer needs while maintaining high standards of quality and reliability in pharmaceutical supply. The company holds certifications from the FDA, FSSAI, and BMC, underscoring its commitment to regulatory compliance and quality assurance.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Client Relationships – Focus on strengthening long-term client associations, enhancing customer loyalty and improving revenue stability.
- Broad Product Portfolio – Diverse and customized product offerings cater to a wide range of customer needs, establishing the company as a comprehensive solutions provider.
- Streamlined Supply Chain Management – Efficient procurement and logistics processes ensure timely delivery, cost optimization, and operational efficiency.
- API & Excipients Expansion Risk: Entry into new segments exposes the company to operational and financial challenges.
- Product Development & Approval Risk: Regulatory delays or market rejection may lead to unsuccessful product launches.
- Customer & Market Concentration Risk: Heavy reliance on limited clients or markets could impact revenue and profitability, especially in the initial phase.
- Samit Madhukar Shah
- Bhavin Dhirendra Shah
- Rahul Dhirendra Shah
- Narendra Nagindas Shah
- Dina Madhukar Shah
- Hemanti Jitendra Shah
Vijaypd Ceutical Limited
Kfin Technologies Limited